SCHEMBL9890733

SCHEMBL9890733

NC(=O)Cc1ccc(F)cc1-c1cccc(Cl)c1

nearest known ligand 0.44

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
ICMT O60725 3/20 0.44
CHRM3 P20309 7/20 0.43
CHRM1 P11229 5/20 0.43
CHRM2 P08172 2/20 0.43
PDE4B Q07343 3/20 0.42
MAPK14 Q16539 1/20 0.41
CYP3A4 P08684 1/20 0.41
CYP2C19 P33261 1/20 0.41
PPARG P37231 1/20 0.40
PDE4D Q08499 1/20 0.39
MAP4K4 O95819 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2395113 0.89 CHRM1 (0.45) ICMTCHRM3CHRM1CHRM2PDE4B
SCHEMBL9890764 0.88 ICMT (0.54) ICMT
SCHEMBL9890768 0.88 PDE4B (0.45) CHRM3CHRM1PDE4BCYP3A4CYP2C19
SCHEMBL9890653 0.87 PPARG (0.49) CHRM3CHRM1CHRM2PDE4BCYP3A4
SCHEMBL2395927 0.87 APP (0.42) ICMTCHRM3CHRM1CHRM2
SCHEMBL2394999 0.84 ICMT (0.46) ICMTPPARG
SCHEMBL2393760 0.82 CHRM1 (0.56) CHRM3CHRM1PDE4BCYP3A4CYP2C19
SCHEMBL16416508 0.82 GCGR (0.45) ICMTCHRM3CHRM1CHRM2CYP3A4
SCHEMBL9890780 0.81 ICMT (0.50) ICMT
SCHEMBL9890766 0.81 ICMT (0.45) ICMTMAP4K4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120142771-A1 BIPHENYLACETAMIDE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2012-06-07 US disclosed
US-20120142771-A1 BIPHENYLACETAMIDE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2012-06-07 US disclosed
EP-2374790-A1 BIPHENYLACETAMIDE DERIVATIVE Dainippon Sumitomo Pharma Co., Ltd. (JP) 2011-10-12 EP disclosed
US-20110224304-A1 BIPHENYLACETAMIDE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2011-09-15 US disclosed
US-20110224304-A1 BIPHENYLACETAMIDE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2011-09-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120142771-A1 BIPHENYLACETAMIDE DERIVATIVE HRH3, KCNH3, BRPF3 ICMT 2894/4885CHRM3 298/4885CHRM1 340/4885
US-20110224304-A1 BIPHENYLACETAMIDE DERIVATIVE HRH3, KCNH3, BRPF3 ICMT 2894/4885CHRM3 298/4885CHRM1 340/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.